Illumina has launched a new research test co-developed with Merck, signaling a strengthening collaboration in the biopharmaceutical field. Merck's stock has surged 21.5% this year, outperforming its industry, as the company anticipates significant growth from its blockbuster drugs Keytruda and Gardasil. The company expects Gardasil sales to potentially double by 2030 and is pursuing the acquisition of Seagen Inc., underscoring its strategic focus on expanding its innovative healthcare solutions.
“Illumina · announced the launch of · a research test co-developed with Merck · this month”
“Merck MRK · boasts · blockbuster drugs · more than six”
“Merck · has a Zacks Rank · Buy · #2”
“Earnings estimates for Merck · have risen · per share · $7.31”
“Merck stock · has risen · this year · 19.9%”
“Merck · has agreements for providing · courses of COVID therapy · approximately 10 million”
“Merck · expects · over half of Keytruda’s growth · to come from indications in early-stage treatment settings through 2025”
“Merck’s stock · has risen · 21.5% · this year so far compared with an increase of 5.9% for the industry”
“Illumina · is making very promising partnership deals with · Merck (NYSE:MRK), AstraZeneca (NASDAQ:AZN), and the Department of Veteran Affairs”
“Merck expects · over half of Keytruda’s growth to come from · indications in early-stage treatment · by 2025”
“Merck expects Gardasil sales to potentially double by · 2030”
“Merck & Co., Inc. MRK · is making efforts to · acquire · Seagen Inc.”
